{"id":69696,"date":"2026-07-09T21:27:37","date_gmt":"2026-07-09T13:27:37","guid":{"rendered":"https:\/\/flcube.com\/?p=69696"},"modified":"2026-07-09T21:27:38","modified_gmt":"2026-07-09T13:27:38","slug":"astellas-pharma-submits-bla-to-china-nmpa-for-padcev-keytruda-combination-in-muscle-invasive-bladder-cancer-showing-60-reduction-in-recurrence-risk-for-cisplatin-ineligible-patients","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69696","title":{"rendered":"Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Astellas Pharma Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/4503:TYO\">TYO: 4503<\/a>) announced that China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has accepted the <strong>Biologics License Application (BLA)<\/strong> for <strong>PADCEV\u00ae (enfortumab vedotin)<\/strong> in combination with <strong>Keytruda\u00ae (pembrolizumab)<\/strong> as a perioperative treatment regimen for adults with <strong>muscle-invasive bladder cancer (MIBC)<\/strong>. The therapy is indicated for use as <strong>neoadjuvant treatment before surgery<\/strong>, followed by <strong>adjuvant treatment after cystectomy<\/strong>, regardless of patients&#8217; eligibility for cisplatin-containing chemotherapy.<\/p>\n\n\n\n<h2 id=\"h-regulatory-filing-details\" class=\"wp-block-heading\">Regulatory Filing Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Applicant<\/strong><\/td><td>Astellas Pharma Inc. (TYO: 4503)<\/td><\/tr><tr><td><strong>Regulatory Agency<\/strong><\/td><td>China National Medical Products Administration (NMPA)<\/td><\/tr><tr><td><strong>Application Type<\/strong><\/td><td>Biologics License Application (BLA)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>PADCEV (enfortumab vedotin) + Keytruda (pembrolizumab)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Perioperative treatment of muscle-invasive bladder cancer (MIBC)<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>All MIBC patients regardless of cisplatin eligibility<\/td><\/tr><tr><td><strong>Supporting Trials<\/strong><\/td><td>Phase 3 EV-303 (KEYNOTE-905) and EV-304 (KEYNOTE-B15)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-clinical-trial-results-dual-population-strategy\" class=\"wp-block-heading\">Clinical Trial Results \u2013 Dual Population Strategy<\/h2>\n\n\n\n<h3 id=\"h-ev-303-trial-cisplatin-ineligible-or-declined-patients\" class=\"wp-block-heading\">EV-303 Trial: Cisplatin-Ineligible or Declined Patients<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><em>Comparison: PADCEV + Keytruda vs. Surgery Alone<\/em><\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Hazard Ratio<\/th><th>Risk Reduction<\/th><th>Statistical Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>Event-Free Survival (EFS)<\/strong><\/td><td>HR 0.40<\/td><td>60%<\/td><td>p&lt;0.0001<\/td><\/tr><tr><td><strong>Overall Survival (OS)<\/strong><\/td><td>HR 0.50<\/td><td>50%<\/td><td>p&lt;0.0001<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 id=\"h-ev-304-trial-cisplatin-eligible-patients\" class=\"wp-block-heading\">EV-304 Trial: Cisplatin-Eligible Patients<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><em>Comparison: PADCEV + Keytruda vs. Standard Gemcitabine\/Cisplatin Chemotherapy<\/em><\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Hazard Ratio<\/th><th>Risk Reduction<\/th><th>Statistical Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>Event-Free Survival (EFS)<\/strong><\/td><td>HR 0.53<\/td><td>47%<\/td><td>p&lt;0.0001<\/td><\/tr><tr><td><strong>Overall Survival (OS)<\/strong><\/td><td>HR 0.65<\/td><td>35%<\/td><td>p&lt;0.001<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 id=\"h-safety-profile\" class=\"wp-block-heading\">Safety Profile<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Consistent with prior experience with the combination<\/li>\n\n\n\n<li>No new safety signals observed in either trial<\/li>\n\n\n\n<li>Manageable adverse event profile supporting perioperative use<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context-amp-therapeutic-innovation\" class=\"wp-block-heading\">Market Context &amp; Therapeutic Innovation<\/h2>\n\n\n\n<h3 id=\"h-muscle-invasive-bladder-cancer-landscape\" class=\"wp-block-heading\">Muscle-Invasive Bladder Cancer Landscape<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Incidence:<\/strong> Approximately 15,000-20,000 new MIBC cases annually in China<\/li>\n\n\n\n<li><strong>Current Standard:<\/strong> Neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy<\/li>\n\n\n\n<li><strong>Treatment Gap:<\/strong> 40-50% of patients are ineligible for cisplatin due to renal impairment, hearing loss, or other comorbidities<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-paradigm-shifting-approach\" class=\"wp-block-heading\">Paradigm-Shifting Approach<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The PADCEV-Keytruda combination represents the first perioperative immunotherapy-antibody drug conjugate (ADC) regimen to demonstrate superior outcomes across both cisplatin-eligible and ineligible populations. This dual-population efficacy addresses the critical unmet need for effective alternatives to cisplatin-based chemotherapy while simultaneously improving outcomes for patients who can tolerate standard therapy.<\/p>\n\n\n\n<h2 id=\"h-commercial-implications-for-chinese-market\" class=\"wp-block-heading\">Commercial Implications for Chinese Market<\/h2>\n\n\n\n<h3 id=\"h-market-opportunity\" class=\"wp-block-heading\">Market Opportunity<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Total Addressable Population:<\/strong> ~15,000-20,000 MIBC patients annually in China<\/li>\n\n\n\n<li><strong>Cisplatin-Ineligible Segment:<\/strong> ~7,000-10,000 patients representing immediate market opportunity<\/li>\n\n\n\n<li><strong>Premium Pricing Potential:<\/strong> Significant clinical benefit supports premium reimbursement positioning<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-competitive-advantages\" class=\"wp-block-heading\">Competitive Advantages<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First-Mover Status:<\/strong> First perioperative ADC-immunotherapy combination in Chinese MIBC market<\/li>\n\n\n\n<li><strong>Broad Applicability:<\/strong> Single regimen serves entire MIBC population regardless of cisplatin eligibility<\/li>\n\n\n\n<li><strong>Survival Benefit:<\/strong> Unprecedented 50-60% reduction in death risk for high-need patient segment<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-significance-for-astellas-pharma\" class=\"wp-block-heading\">Strategic Significance for Astellas Pharma<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">This BLA submission represents a major milestone in Astellas&#8217; global oncology strategy and demonstrates successful execution of its partnership with Merck (Keytruda developer). The dual-trial approach\u2014simultaneously addressing both cisplatin-eligible and ineligible populations\u2014maximizes market penetration potential and establishes a new standard of care across the entire MIBC spectrum.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">China represents one of the world&#8217;s largest bladder cancer markets, and approval would position Astellas to capture significant market share in a high-value oncology indication with substantial unmet medical need. The perioperative setting also creates opportunities for long-term patient relationships and potential expansion into other urothelial cancer indications.<\/p>\n\n\n\n<h2 id=\"h-development-timeline-amp-next-steps\" class=\"wp-block-heading\">Development Timeline &amp; Next Steps<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Q3-Q4 2026:<\/strong> NMPA review process with potential priority review designation<\/li>\n\n\n\n<li><strong>2027:<\/strong> Expected approval decision and commercial launch preparation<\/li>\n\n\n\n<li><strong>2027+:<\/strong> Integration into Chinese clinical guidelines and reimbursement negotiations<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory submissions, clinical trial results, and commercial expectations. Actual results may differ materially due to regulatory decisions, competitive developments, market acceptance, and other risk factors detailed in Astellas Pharma&#8217;s SEC filings.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Astellas Pharma Inc. (TYO: 4503) announced that China&#8217;s National Medical Products Administration (NMPA) has accepted&#8230;<\/p>\n","protected":false},"author":1,"featured_media":69698,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[353,16,17,29,18,1177],"class_list":["post-69696","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-astellas-pharma","tag-cancer","tag-clinical-trial-results","tag-combination-therapy","tag-pd-1-l1","tag-tyo-4503"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Astellas Pharma Inc. (TYO: 4503) announced that China&#039;s National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for PADCEV\u00ae (enfortumab vedotin) in combination with Keytruda\u00ae (pembrolizumab) as a perioperative treatment regimen for adults with muscle-invasive bladder cancer (MIBC). The therapy is indicated for use as neoadjuvant treatment before surgery, followed by adjuvant treatment after cystectomy, regardless of patients&#039; eligibility for cisplatin-containing chemotherapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69696\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients\" \/>\n<meta property=\"og:description\" content=\"Astellas Pharma Inc. (TYO: 4503) announced that China&#039;s National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for PADCEV\u00ae (enfortumab vedotin) in combination with Keytruda\u00ae (pembrolizumab) as a perioperative treatment regimen for adults with muscle-invasive bladder cancer (MIBC). The therapy is indicated for use as neoadjuvant treatment before surgery, followed by adjuvant treatment after cystectomy, regardless of patients&#039; eligibility for cisplatin-containing chemotherapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69696\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-09T13:27:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-09T13:27:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0905.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69696#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69696\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients\",\"datePublished\":\"2026-07-09T13:27:37+00:00\",\"dateModified\":\"2026-07-09T13:27:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69696\"},\"wordCount\":576,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69696#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0905.webp\",\"keywords\":[\"Astellas Pharma\",\"Cancer\",\"Clinical trial results\",\"Combination therapy\",\"PD-1\\\/L1\",\"TYO: 4503\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69696#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69696\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69696\",\"name\":\"Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69696#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69696#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0905.webp\",\"datePublished\":\"2026-07-09T13:27:37+00:00\",\"dateModified\":\"2026-07-09T13:27:38+00:00\",\"description\":\"Astellas Pharma Inc. (TYO: 4503) announced that China's National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for PADCEV\u00ae (enfortumab vedotin) in combination with Keytruda\u00ae (pembrolizumab) as a perioperative treatment regimen for adults with muscle-invasive bladder cancer (MIBC). The therapy is indicated for use as neoadjuvant treatment before surgery, followed by adjuvant treatment after cystectomy, regardless of patients' eligibility for cisplatin-containing chemotherapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69696#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69696\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69696#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0905.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0905.webp\",\"width\":1080,\"height\":608,\"caption\":\"Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69696#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients - Insight, China&#039;s Pharmaceutical Industry","description":"Astellas Pharma Inc. (TYO: 4503) announced that China's National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for PADCEV\u00ae (enfortumab vedotin) in combination with Keytruda\u00ae (pembrolizumab) as a perioperative treatment regimen for adults with muscle-invasive bladder cancer (MIBC). The therapy is indicated for use as neoadjuvant treatment before surgery, followed by adjuvant treatment after cystectomy, regardless of patients' eligibility for cisplatin-containing chemotherapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69696","og_locale":"en_US","og_type":"article","og_title":"Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients","og_description":"Astellas Pharma Inc. (TYO: 4503) announced that China's National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for PADCEV\u00ae (enfortumab vedotin) in combination with Keytruda\u00ae (pembrolizumab) as a perioperative treatment regimen for adults with muscle-invasive bladder cancer (MIBC). The therapy is indicated for use as neoadjuvant treatment before surgery, followed by adjuvant treatment after cystectomy, regardless of patients' eligibility for cisplatin-containing chemotherapy.","og_url":"https:\/\/flcube.com\/?p=69696","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-09T13:27:37+00:00","article_modified_time":"2026-07-09T13:27:38+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0905.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69696#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69696"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients","datePublished":"2026-07-09T13:27:37+00:00","dateModified":"2026-07-09T13:27:38+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69696"},"wordCount":576,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=69696#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0905.webp","keywords":["Astellas Pharma","Cancer","Clinical trial results","Combination therapy","PD-1\/L1","TYO: 4503"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69696#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69696","url":"https:\/\/flcube.com\/?p=69696","name":"Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=69696#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=69696#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0905.webp","datePublished":"2026-07-09T13:27:37+00:00","dateModified":"2026-07-09T13:27:38+00:00","description":"Astellas Pharma Inc. (TYO: 4503) announced that China's National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for PADCEV\u00ae (enfortumab vedotin) in combination with Keytruda\u00ae (pembrolizumab) as a perioperative treatment regimen for adults with muscle-invasive bladder cancer (MIBC). The therapy is indicated for use as neoadjuvant treatment before surgery, followed by adjuvant treatment after cystectomy, regardless of patients' eligibility for cisplatin-containing chemotherapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69696#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69696"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=69696#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0905.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0905.webp","width":1080,"height":608,"caption":"Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69696#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0905.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69696","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69696"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69696\/revisions"}],"predecessor-version":[{"id":69699,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69696\/revisions\/69699"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/69698"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69696"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69696"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69696"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}